Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7736541rdf:typepubmed:Citationlld:pubmed
pubmed-article:7736541lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:7736541lifeskim:mentionsumls-concept:C0205147lld:lifeskim
pubmed-article:7736541lifeskim:mentionsumls-concept:C0003242lld:lifeskim
pubmed-article:7736541lifeskim:mentionsumls-concept:C0016897lld:lifeskim
pubmed-article:7736541lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:7736541lifeskim:mentionsumls-concept:C1880177lld:lifeskim
pubmed-article:7736541lifeskim:mentionsumls-concept:C1176299lld:lifeskim
pubmed-article:7736541pubmed:dateCreated1995-6-2lld:pubmed
pubmed-article:7736541pubmed:abstractTextPreviously we developed a murine monoclonal anti-idiotype (anti-id) antibody (4C10) that mimics the melanoma-associated ganglioside antigen GM3, that is, it carries the internal image of GM3. 4C10 was made against the human monoclonal antibody (HuMAb) L612, which reacts with several types of human cancer cells, including melanoma and breast cancer. To reduce mouse components of 4C10, the constant region was replaced by a human constant domain to form the murine/human chimeric anti-id antibody TVE-1. In the present study, we sought to determine which chain (VH or VL) of the anti-id is responsible for the antigenicity of GM3. The TVE-1 VH and VL expression vectors were simultaneously transfected with either the VH or VL expression vector of a murine-human chimeric IgG antidansyl haptenic antibody, resulting in the construction of three different combinations of VH and VL chimeric antibodies. These IgG molecules were produced from the transfectomas, and their reactivity to HuMAb L612 was tested. Neither of the IgG proteins that had cross-combined the VH-VL pair showed positive results, suggesting that both heavy and light chains are required to express the antigenicity. The in vivo antigenicity of this chimeric anti-id was confirmed by skin tests in melanoma patients receiving active specific immunotherapy.lld:pubmed
pubmed-article:7736541pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7736541pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7736541pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7736541pubmed:languageenglld:pubmed
pubmed-article:7736541pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7736541pubmed:citationSubsetIMlld:pubmed
pubmed-article:7736541pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7736541pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7736541pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7736541pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7736541pubmed:statusMEDLINElld:pubmed
pubmed-article:7736541pubmed:issn0163-4992lld:pubmed
pubmed-article:7736541pubmed:authorpubmed-author:MortonD LDLlld:pubmed
pubmed-article:7736541pubmed:authorpubmed-author:IrieR FRFlld:pubmed
pubmed-article:7736541pubmed:authorpubmed-author:TakeyamaHHlld:pubmed
pubmed-article:7736541pubmed:authorpubmed-author:MorrisonS LSLlld:pubmed
pubmed-article:7736541pubmed:authorpubmed-author:KandaSSlld:pubmed
pubmed-article:7736541pubmed:authorpubmed-author:KikumotoYYlld:pubmed
pubmed-article:7736541pubmed:issnTypePrintlld:pubmed
pubmed-article:7736541pubmed:volume24-25lld:pubmed
pubmed-article:7736541pubmed:ownerNLMlld:pubmed
pubmed-article:7736541pubmed:authorsCompleteYlld:pubmed
pubmed-article:7736541pubmed:pagination65-74lld:pubmed
pubmed-article:7736541pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7736541pubmed:meshHeadingpubmed-meshheading:7736541-...lld:pubmed
pubmed-article:7736541pubmed:meshHeadingpubmed-meshheading:7736541-...lld:pubmed
pubmed-article:7736541pubmed:meshHeadingpubmed-meshheading:7736541-...lld:pubmed
pubmed-article:7736541pubmed:meshHeadingpubmed-meshheading:7736541-...lld:pubmed
pubmed-article:7736541pubmed:meshHeadingpubmed-meshheading:7736541-...lld:pubmed
pubmed-article:7736541pubmed:meshHeadingpubmed-meshheading:7736541-...lld:pubmed
pubmed-article:7736541pubmed:meshHeadingpubmed-meshheading:7736541-...lld:pubmed
pubmed-article:7736541pubmed:meshHeadingpubmed-meshheading:7736541-...lld:pubmed
pubmed-article:7736541pubmed:year1994lld:pubmed
pubmed-article:7736541pubmed:articleTitleBoth VH and VL regions contribute to the antigenicity of anti-idiotypic antibody that mimics melanoma associated ganglioside GM3.lld:pubmed
pubmed-article:7736541pubmed:affiliationDepartment of Surgical Oncology, UCLA School of Medicine.lld:pubmed
pubmed-article:7736541pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7736541pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7736541pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed